Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Journal of Hepatology

Volumn 58, Issue 4, 2013, Pages 655-662

  Suzuki, Yoshiyuki ^a   Ikeda, Kenji ^a   Suzuki, Fumitaka ^a   Toyota, Joji ^b   Karino, Yoshiyasu ^b   Chayama, Kazuaki ^c   Kawakami, Yoshiiku ^c   Ishikawa, Hiroki ^d   Watanabe, Hideaki ^d   Hu, Wenhua ^e   Eley, Timothy ^e   McPhee, Fiona ^e   Hughes, Eric ^f   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d Bristol Myers KK   (Japan)

^e BRISTOL MYERS SQUIBB   (United States)

^f BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antiviral; Asunaprevir; Daclatasvir; Hepatitis C

Indexed keywords

ASUNAPREVIR; DACLATASVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPOCHONDRIASIS; JAPANESE; MALE; MICROBIOLOGICAL PARAMETERS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; MIDDLE AGED; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84879693219     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.09.037     Document Type: Article

References (26)

1. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
2. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
3. T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg, and S. Flamm Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
4. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. J.M. Vierling, S.L. Flamm, S.C. Gordon, E. Lawitz, J.P. Bronowicki, and M. Davis Efficacy of boceprevir in prior null responders to peginterferon/ ribavirin: the PROVIDE study [abstract] Hepatology 54 2011 796A 797A
6. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, and R. Elston Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
7. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, and H. Ishikawa Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders Hepatology 55 2012 742 748
8. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
9. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, E. Ceausu, and A.W. Lohse Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study [abstract] Hepatology 54 2011 1436A
10. E.J. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, and R. Hindes Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 [abstract] Hepatology 54 2011 377A
11. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 54 2010 3641 3650
12. F. McPhee, J. Friborg, S. Levine, C. Chen, P. Falk, and F. Yu Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir Antimicrob Agents Chemother 2012 10.1128/AAC.00308-12
13. M. Bifano, H. Sevinsky, B.R. Bedford, J. Coumbis, T. Eley, and S.P. Huang Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects [abstract] Hepatology 52 2010 719A
14. J.P. Bronowicki, S. Pol, P.J. Thuluvath, D. Larrey, C.T. Martorell, and V.K. Rustgi BMS-650032, an NS3 inhibitor, in combination with peginterferon alfa-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection [abstract] J Hepatol 54 2011 S472
15. G. Sebastiani, L. Castera, P. Halfon, S. Pol, A. Mangia, and V. Di Marco The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases Aliment Pharmacol Ther 34 2011 1202 1216
16. W. Sievert, I. Altraif, H.A. Razavi, A. Abdo, E.A. Ahmed, and A. Alomair A systematic review of hepatitis C virus epidemiology in Asia Australia Egypt Liver Int 31 2011 61 80
17. M. Kurosaki, Y. Tanaka, N. Nishida, N. Sakamoto, N. Enomoto, and M. Honda Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors J Hepatol 54 2011 439 448
18. M. Kobayashi, F. Suzuki, N. Akuta, H. Sezaki, Y. Suzuki, and T. Hosaka Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus J Gastroenterol 2012 10.1007/s00535-012-0531-1
19. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
20. S. Zeuzem, G.R. Foster, M.W. Fried, C. Hezode, G.M. Hirschfleld, and I. Nikitin The ASPIRE trial: TMC435 in treatment-experienced patients with genotype-1 HCV infection who have failed previous pegIFN/RBV treatment [abstract] J Hepatol 54 2011 S546
21. S.M. Horner, and M. Gale Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus J Interferon Cytokine Res 29 2009 489 498
22. J. Heathcote Retreatment of chronic hepatitis C: who and how? Liver Int 29 2009 49 56
23. M.T. Melia, A.J. Muir, J. McCone, M.L. Shiffman, J.W. King, and S.K. Herrine Racial differences in hepatitis C treatment eligibility Hepatology 54 2011 70 78
24. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
25. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
26. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838